Gene therapies are game changers to treat incurable genetic diseases and cancers.

With production costs superior to 1m$/patient, large scale manufacturing of their key component, viral vectors, remains the blocking point to scale up and make gene therapies more affordable.

Kolibri creates the next-generation of bioproduction technologies reducing viral vector production costs up to 95%. Their proprietary bioreactor combines cutting edge acoustic techniques to drastically reduce the cost of manufacturing and further increase the quality of the end-product.